|
1
|
Holschneider CH and Berek JS: Ovarian
cancer: Epidemiology, biology, and prognostic factors. Semin Surg
Oncol. 19:3–10. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chiang YC, Chen CA, Chiang CJ, Hsu TH, Lin
MC, You SL, Cheng WF and Lai MS: Trends in incidence and survival
outcome of epithelial ovarian cancer: 30-Year national
population-based registry in Taiwan. J Gynecol Oncol. 24:342–351.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Austin RM: Benign to malignant
transformation in epithelial ovarian tumors. Hum Pathol.
24:562–563. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fitzgibbons PL, Henson DE and Hutter RV:
Cancer Committee of the College of American Pathologists: Benign
breast changes and the risk for subsequent breast cancer: An update
of the 1985 consensus statement. Arch Pathol Lab Med.
122:1053–1055. 1998.PubMed/NCBI
|
|
6
|
Dupont WD, Page DL, Parl FF, Vnencak-Jones
CL, Plummer WD Jr, Rados MS and Schuyler PA: Long-term risk of
breast cancer in women with fibroadenoma. N Engl J Med. 331:10–15.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McDivitt RW, Stevens JA, Lee NC, Wingo PA,
Rubin GL and Gersell D: The Cancer and Steroid Hormone Study Group:
Histologic types of benign breast disease and the risk for breast
cancer. Cancer. 69:1408–1414. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Powell DE, Puls L and van Nagell J Jr:
Current concepts in epithelial ovarian tumors: Does benign to
malignant transformation occur? Hum Pathol. 23:846–847. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Waldemarson S, Krogh M, Alaiya A, Kirik U,
Schedvins K, Auer G, Hansson KM, Ossola R, Aebersold R, Lee H, et
al: Protein expression changes in ovarian cancer during the
transition from benign to malignant. J Proteome Res. 11:2876–2889.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de Haan J, Verheecke M and Amant F:
Management of ovarian cysts and cancer in pregnancy. Facts Views
Vis Obgyn. 7:25–31. 2015.PubMed/NCBI
|
|
11
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cabili MN, Trapnell C, Goff L, Koziol M,
Tazon-Vega B, Regev A and Rinn JL: Integrative annotation of human
large intergenic noncoding RNAs reveals global properties and
specific subclasses. Genes Dev. 25:1915–1927. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Silva JM, Boczek NJ, Berres MW, Ma X and
Smith DI: LSINCT5 is over expressed in breast and ovarian cancer
and affects cellular proliferation. RNA Biol. 8:496–505. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Medrzycki M, Zhang Y, Zhang W, Cao K, Pan
C, Lailler N, McDonald JF, Bouhassira EE and Fan Y: Histone h1.3
suppresses h19 noncoding RNA expression and cell growth of
ovarian cancer cells. Cancer Res. 74:6463–6473. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guan Y, Kuo WL, Stilwell JL, Takano H,
Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, et al:
Amplification of PVT1 contributes to the pathophysiology of
ovarian and breast cancer. Clin Cancer Res. 13:5745–5755. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qiu JJ, Wang Y, Ding JX, Jin HY, Yang G
and Hua KQ: The long non-coding RNA HOTAIR promotes the
proliferation of serous ovarian cancer cells through the regulation
of cell cycle arrest and apoptosis. Exp Cell Res. 333:238–248.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gloss B, Moran-Jones K, Lin V, Gonzalez M,
Scurry J, Hacker NF, Sutherland RL, Clark SJ and Samimi G:
ZNF300P1 encodes a lincRNA that regulates cell polarity and
is epigenetically silenced in type II epithelial ovarian cancer.
Mol Cancer. 13:32014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qiu JJ, Lin YY, Ye LC, Ding JX, Feng WW,
Jin HY, Zhang Y, Li Q and Hua KQ: Overexpression of long non-coding
RNA HOTAIR predicts poor patient prognosis and promotes tumor
metastasis in epithelial ovarian cancer. Gynecol Oncol.
134:121–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao
H, Zhong Z and Sun J: Comprehensive analysis of lncRNA expression
profiles reveals a novel lncRNA signature to discriminate
nonequivalent outcomes in patients with ovarian cancer. Oncotarget.
7:32433–32448. 2016.PubMed/NCBI
|
|
20
|
Pelusi G, Taroni B and Flamigni C: Benign
ovarian tumors. Front Biosci. 2:g5–7. 1997.PubMed/NCBI
|
|
21
|
Qiu JJ, Lin YY, Ding JX, Feng WW, Jin HY
and Hua KQ: Long non-coding RNA ANRIL predicts poor prognosis and
promotes invasion/metastasis in serous ovarian cancer. Int J Oncol.
46:2497–2505. 2015.PubMed/NCBI
|
|
22
|
Gao Y, Meng H, Liu S, Hu J, Zhang Y, Jiao
T, Liu Y, Ou J, Wang D, Yao L, et al: LncRNA-HOST2 regulates cell
biological behaviors in epithelial ovarian cancer through a
mechanism involving microRNA let-7b. Hum Mol Genet. 24:841–852.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang H, Fu Z, Dai C, Cao J, Liu X, Xu J,
Lv M, Gu Y, Zhang J, Hua X, et al: LncRNAs expression profiling in
normal ovary, benign ovarian cyst and malignant epithelial ovarian
cancer. Sci Rep. 6:389832016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang J, Chen L, Kong X, Huang T and Cai
YD: Analysis of tumor suppressor genes based on gene ontology and
the KEGG pathway. PLoS One. 9:e1072022014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang EB, Yin DD, Sun M, Kong R, Liu XH,
You LH, Han L, Xia R, Wang KM, Yang JS, et al: P53-regulated long
non-coding RNA TUG1 affects cell proliferation in human non-small
cell lung cancer, partly through epigenetically regulating HOXB7
expression. Cell Death Dis. 5:e12432014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khalil AM, Guttman M, Huarte M, Garber M,
Raj A, Morales Rivea D, Thomas K, Presser A, Bernstein BE, van
Oudenaarden A, et al: Many human large intergenic noncoding RNAs
associate with chromatin-modifying complexes and affect gene
expression. Proc Natl Acad Sci USA. 106:11667–11672. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hendrickson GD, Kelley DR, Tenen D,
Bernstein B and Rinn JL: Widespread RNA binding by
chromatin-associated proteins. Genome Biol. 17:282016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a
hidden RNA language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou M, Wang X, Shi H, Cheng L, Wang Z,
Zhao H, Yang L and Sun J: Characterization of long non-coding
RNA-associated ceRNA network to reveal potential prognostic lncRNA
biomarkers in human ovarian cancer. Oncotarget. 7:12598–12611.
2016.PubMed/NCBI
|
|
30
|
Cole SW, Nagaraja AS, Lutgendorf SK, Green
PA and Sood AK: Sympathetic nervous system regulation of the tumour
microenvironment. Nat Rev Cancer. 15:563–572. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huan HB, Wen XD, Chen XJ, Wu L, Wu LL,
Zhang L, Yang DP, Zhang X, Bie P, Qian C, et al: Sympathetic
nervous system promotes hepatocarcinogenesis by modulating
inflammation through activation of alpha1-adrenergic receptors of
Kupffer cells. Brain Behav Immun. 59:118–134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Magnon C, Hall SJ, Lin J, Xue X, Gerber L,
Freedland SJ and Frenette PS: Autonomic nerve development
contributes to prostate cancer progression. Science.
341:12363612013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luo M, Li Z, Wang W, Zeng Y, Liu Z and Qiu
J: Long non-coding RNA H19 increases bladder cancer metastasis by
associating with EZH2 and inhibiting E-cadherin expression. Cancer
Lett. 333:213–221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hirata H, Hinoda Y, Shahryari V, Deng G,
Nakajima K, Tabatabai ZL, Ishii N and Dahiya R: Long noncoding RNA
MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and
interacts with miR-205. Cancer Res. 75:1322–1331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Crea F, Watahiki A, Quagliata L, Xue H,
Pikor L, Parolia A, Wang Y, Lin D, Lam WL, Farrar WL, et al:
Identification of a long non-coding RNA as a novel biomarker and
potential therapeutic target for metastatic prostate cancer.
Oncotarget. 5:764–774. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou M, Zhong L, Xu W, Sun Y, Zhang Z,
Zhao H, Yang L and Sun J: Discovery of potential prognostic long
non-coding RNA biomarkers for predicting the risk of tumor
recurrence of breast cancer patients. Sci Rep. 6:310382016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhou M, Diao Z, Yue X, Chen Y, Zhao H,
Cheng L and Sun J: Construction and analysis of dysregulated
lncRNA-associated ceRNA network identified novel lncRNA biomarkers
for early diagnosis of human pancreatic cancer. Oncotarget.
7:56383–56394. 2016.PubMed/NCBI
|
|
38
|
Zhou M, Guo M, He D, Wang X, Cui Y, Yang
H, Hao D and Sun J: A potential signature of eight long non-coding
RNAs predicts survival in patients with non-small cell lung cancer.
J Transl Med. 13:2312015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou M, Xu W, Yue X, Zhao H, Wang Z, Shi
H, Cheng L and Sun J: Relapse-related long non-coding RNA signature
to improve prognosis prediction of lung adenocarcinoma. Oncotarget.
7:29720–29738. 2016.PubMed/NCBI
|
|
40
|
Ma Y, Lu Y and Lu B: MicroRNA and long
non-coding RNA in ovarian carcinoma: Translational insights and
potential clinical applications. Cancer Invest. 34:465–476. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yim GW, Kim HJ, Kim LK, Kim SW, Kim S, Nam
EJ and Kim YT: Long non-coding RNA HOXA11 antisense promotes cell
proliferation and invasion and predicts patient prognosis in serous
ovarian cancer. Cancer Res Treat. Oct 11–2016.(Epub ahead of
print). doi: 10.4143/crt.2016.263. View Article : Google Scholar :
|
